Aberrant innate immune responses in TLR-ligand activated HLA-B27 transgenic rat cells

Inflammatory Bowel Diseases

Volumn 14, Issue 10, 2008, Pages 1358-1365

  Qian, Bi Feng ^a   Tonkonogy, Susan L ^a,b   Sartor, R Balfour ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Bacterial adjuvants; HLA B27 transgenic rats; Innate immune responses; Splenocytes; Toll like receptors

Indexed keywords

ADJUVANT; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CD11B ANTIGEN; CYTOKINE; DNA; HLA B27 ANTIGEN; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MESSENGER RNA; PEPTIDOGLYCAN; POLYSACCHARIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL COMPOSITION; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENTEROBACTERIACEAE; FEMALE; GERMFREE ANIMAL; INFLAMMATORY CELL; INNATE IMMUNITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; RAT; SIGNAL TRANSDUCTION; SPLEEN CELL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TRANSGENIC RAT; ANIMAL; BACTERIUM; CYTOLOGY; FISCHER 344 RAT; FLOW CYTOMETRY; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; SPLEEN; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; BACTERIA; COLITIS; FLOW CYTOMETRY; GENE EXPRESSION; GERM-FREE LIFE; HLA-B27 ANTIGEN; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-10; RATS; RATS, INBRED F344; RATS, TRANSGENIC; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; T-LYMPHOCYTE SUBSETS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 59749095339     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20502     Document Type: Article

References (57)

1. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577-594.
2. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17:1-14.
3. Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. J Immunol. 2005;174:4453-4460.
4. Cario E, Podolsky DK. Toll-like receptor signaling and its relevance to intestinal inflammation. Ann N Y Acad Sci. 2006;1072:332-338.
5. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603.
6. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411: 603-606.
7. Torok HP, Glas J, Tonenchi L, et al. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol. 2004;112:85-91.
8. Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut. 2004;53:987-992.
9. Pierik M, Joossens S, Van Steen K, et al. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis. 2006;12:1-8.
10. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol. 1995;102:448-455.
11. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto-and microbial antigens. Gastroenterology. 2002;123:689-699.
12. Dieleman LA, Hoentjen F, Qian B-F, et al. Reduced ratio of protective versus proinflammatory cytokine responses to commensal bacteria in HLA-B27 transgenic rats. Clin Exp Immunol. 2004;136:30-39.
13. Qian BF, Tonkonogy SL, Hoentjen F, et al. Dysregulated luminal bacterial antigen-specific T-cell responses and antigen-presenting cell function in HLA-B27 transgenic rats with chronic colitis. Immunology. 2005;116:112-121.
14. Albright C, Tonkonogy SL, Sartor RB. Antigen presenting cells produce IL-10 in response to IFN-γ. Gastroenterology. 2003;124(suppl 1):A332.
15. Cong Y, Brandwein SL, McCabe RP, et al. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med. 1998;187:855-864.
16. Hausmann M, Kiessling S, Mestermann S, et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology. 2002;122:1987-2000.
17. Hart AL, Al-Hassi HO, Rigby RJ, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology. 2005;129:50-65.
18. Fort MM, Mozaffarian A, Stover AG, et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol. 2005;174:6416-6423.
19. Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180:2359-2364.
20. Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell. 1990;63:1099-1112.
21. Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest. 1996;98:945-953.
22. Breban M, Fernandez-Sueiro JL, Richardson JA, et al. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol. 1996;156:794-803.
23. Hoentjen F, Tonkonogy SL, Liu B, et al. Adoptive transfer of nontransgenic mesenteric lymph node cells induces colitis in athymic HLA-B27 transgenic nude rats. Clin Exp Immunol. 2006;143:474-483.
24. Breban M, Hammer RE, Richardson JA, et al. Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment. J Exp Med. 1993;178:1607-1616.
25. Qian BF, Tonkonogy SL, Balfour Sartor R. Luminal bacterial antigen-specific CD4+ T-cell responses in HLA-B27 transgenic rats with chronic colitis are mediated by both major histocompatibility class II and HLA-B27 molecules. Immunology. 2006;117:319-328.
26. McCall RD, Haskill S, Zimmermann EM, et al. Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats. Gastroenterology. 1994; 106:960-972.
27. Krook H, Hagberg A, Song Z, et al. A distinct Th1 immune response precedes the described Th2 response in islet xenograft rejection. Diabetes. 2002;51:79-86.
28. Chiffoleau E, Heslan JM, Heslan M, et al. TLR9 ligand enhances proliferation of rat CD4+ T cell and modulates suppressive activity mediated by CD+ CD25 T cell. Int Immunol. 2007;19:193-201.
29. Kitani A, Fuss IJ, Nakamura K, et al. Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. J Exp Med. 2000;192:41-52.
30. Qian BF, Tonkonogy SL, Sartor RB. Reduced responsiveness of HLA-B27 transgenic rat cells to TGF-β and IL-10-mediated regulation of IFN-γ production. Inflamm Bowel Dis. 2008 (in press).
31. de Jong EC, Smits HH, Kapsenberg ML. Dendritic cell-mediated T cell polarization. Springer Semin Immunopathol. 2005;26:289-307.
32. Kabelitz D, Wesch D, Oberg HH. Regulation of regulatory T cells: role of dendritic cells and toll-like receptors. Crit Rev Immunol. 2006;26: 291-306.
33. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235-238.
34. Fong Y, Tracey KJ, Moldawer LL, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med. 1989;170:1627-1633.
35. Cope AP, Liblau RS, Yang XD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med. 1997;185:1573-1584.
36. Aspalter RM, Eibl MM, Wolf HM. Regulation of TCR-mediated T cell activation by TNF-RII. J Leukoc Biol. 2003;74:572-582.
37. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
38. Spencer SD, Di Marco F, Hooley J, et al. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med. 1998;187:571-578.
39. Takeda K, Clausen BE, Kaisho T, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity. 1999;10:39-49.
40. Powrie F, Leach MW, Mauze S, et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994;1:553-562.
41. Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest. 1996;98: 1010-1020.
42. Asseman C, Mauze S, Leach MW, et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999;190:995-1004.
43. Cong Y, Weaver CT, Lazenby A, et al. Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to the enteric flora. J Immunol. 2002;169:6112-6119.
44. Van Montfrans C, Rodriguez Pena MS, Pronk I, et al. Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model. Gastroenterology. 2002;123:1865-1876.
45. Pestka S, Krause CD, Sarkar D, et al. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004;22:929-979.
46. Muzio M, Bosisio D, Polentarutti N, et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol. 2000;164:5998-6004.
47. Tamandl D, Bahrami M, Wessner B, et al. Modulation of toll-like receptor 4 expression on human monocytes by tumor necrosis factor and interleukin-6: tumor necrosis factor evokes lipopolysaccharide hyporesponsiveness, whereas interleukin-6 enhances lipopolysaccharide activity. Shock. 2003;20:224-229.
48. Mueller T, Terada T, Rosenberg IM, et al. Th2 cytokines down-regulate TLR expression and function in human intestinal epithelial cells. J Immunol. 2006;176:5805-5814.
49. McCartney-Francis N, Jin W, Wahl SM. Aberrant Toll receptor expression and endotoxin hypersensitivity in mice lacking a functional TGF-beta 1 signaling pathway. J Immunol. 2004;172:3814-3821.
50. Ruiz PA, Shkoda A, Kim SC, et al. IL-10 gene-deficient mice lack TGF-beta/Smad signaling and fail to inhibit proinflammatory gene expression in intestinal epithelial cells after the colonization with colitogenic Enterococcus faecalis. J Immunol. 2005;174:2990-2999.
51. Kollnberger S, Bird LA, Roddis M, et al. HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-like receptors. J Immunol. 2004;173:1699-1710.
52. De Rycke L, Vandooren B, Kruithof E, et al. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum. 2005;52:2146-2158.
53. Shibolet O, Podolsky DK. TLRs in the gut. IV. Negative regulation of Toll-like receptors and intestinal homeostasis: addition by subtraction. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1469-1473.
54. Melmed G, Thomas LS, Lee N, et al. Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol. 2003;170:1406-1415.
55. Otte JM, Cario E, Podolsky DK. Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology. 2004;126:1054-1070.
56. Wald D, Qin J, Zhao Z, et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol. 2003;4:920-927.
57. Garlanda C, Riva F, Polentarutti N, et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci U S A. 2004;101:3522-3526.